{"count":5,"limit":50,"offset":0,"edits":[{"id":4986,"actor_id":null,"entity_type":"hypothesis","entity_id":"h-var-4eca108177","action":"update","diff_json":{"after":"2026-04-20 19:54:50.595930-07:00","before":"2026-04-20 06:26:26.993470-07:00"},"change_reason":"enrich EC-II vulnerability hypotheses with evidence addenda","created_at":"2026-04-21T02:54:50.595930+00:00"},{"id":4987,"actor_id":null,"entity_type":"hypothesis","entity_id":"h-var-4eca108177","action":"update","diff_json":{"after":"'2':832 '2023':817 '27929004':928 '28111080':897 '30155285':960 '34027028':958 '36513524':863 '39435008':813 '39803521':815 '40':908 '5xfad':186 'aberr':576 'accept':945 'accumul':176 'across':514 'action':232,506 'activ':254,580,779,887,943,1112,1370 'actual':995 'ad':21,810,824,895,925,998,1125 'addendum':704 'addit':905 'adjac':559 'advanc':378 'afterhyperpolar':236 'ai':18,58,90,665,715,1144,1182,1357 'alloster':347 'also':825 'alter':196,885,918,1321 'altern':278 'alzheim':64,648,699,761 'amplifi':363 'amplitud':199,234,430 'amyloid':590,919,1325 'amyloid-link':1324 'anatom':552 'anchor':80 'anim':229,1291 'ankyr':74,98,171,663,1355 'ankyring-depend':662,1354 'approach':292,380 'arous':1015 'assay':214,1073 'assess':486 'associ':588 'attent':1106 'axe':978 'axon':55 'base':385,463,485,533,727 'basket':51 'begin':781 'behavior':213,1072,1305 'benefit':1329 'biomark':412,440,459,1037 'blind':1301 'block':16 'braak':763 'brain':383,560 'branch':900 'broad':1092 'built':1241 'burden':467,920 'burst':1369 'bystand':861 'ca1':847 'ca3':845 'capac':115 'captur':1021 'cascad':762 'caus':1009 'caveat':1217 'cell':52,62,133,179,217,748,793,883,989,1177,1258 'cell-typ':792,1257 'cell-type-resolv':1176 'cellular':680 'center':1220 'cerebrospin':444 'chain':454 'challeng':508,545 'chandeli':61 'chang':768,1069 'channel':85,359 'characterist':646 'circuit':147,627,755,1023,1284 'claim':743,1310 'clamp':220 'clinic':495,932 'close':2,275,305,1155,1297 'closed-loop':1,274,304,1154,1296 'cluster':87 'co':343 'co-treat':342 'cognit':267,683,1030,1093 'coher':436,1138,1186 'coincid':173 'come':1104 'compar':242 'compromis':109 'concern':570 'confirm':222,1044,1282 'connect':481,592 'contact':59 'contribut':636 'control':126,247,855,1200,1335 'converg':672,1036 'correl':206 'cortex':36,166,285,540,821,1345 'cortic':586,787,1111,1207 'could':361,393,455,1103 'counterevid':1214 'coupl':200,336,431,1065 'creat':604 'critic':76,628 'cross':334,434 'cross-frequ':333 'cross-region':433 'current':107,279,395,548 'cycl':609 'damag':471,523 'decreas':231 'deficit':635,891 'degrad':880,1147 'deliv':321 'deliveri':396 'demonstr':157,251,1096,1267 'densiti':108,417 'dentat':843 'depend':664,1356 'design':1279 'desynchron':1365 'detect':316 'differ':563 'diffus':390 'direct':499,677 'disappear':1331 'discount':1234 'diseas':66,650,701,1045,1263 'disease-stag':1262 'dispers':103 'displac':99 'disrupt':19,69,127,660,716,1145 'dose':357 'downstream':860 'drive':1170 'due':546 'dynam':565 'dysfunct':612,697,742,822 'earli':639,766,894,930,1022 'ec':7,719,730,830,850,867,969,1055,1097,1188,1206,1255,1316 'ec-ii':6,849,968,1315 'ec-tau':866 'ec-to-hippocamp':718 'ecii':706 'ecii-pv-gamma-rhythmogenesi':705 'eeg':313,418 'eeg/meg':1059 'effect':366,411 'efficaci':952 'electrophysiolog':180,439 'encod':141,339 'endogen':317 'endpoint':414,497,1094,1196,1306 'engag':1098,1256,1314 'enhanc':329,360 'enrich':703 'entorhin':35,145,165,183,284,402,479,539,625,741,754,799,820,1344 'entorhinal-hippocamp':144,478,624 'entrain':298,911,940,1162 'envelop':1213 'episod':491,643 'essenti':116 'evalu':974 'evid':149,702,726,749,1060 'ex':1288 'exchang':1249 'excitatori':877 'exhibit':230 'experi':250,1275 'expos':1223 'express':153 'failur':1312,1319 'falsifi':1311 'famili':734 'fast':31,1133,1360 'fast-spik':30 'feasibl':931 'feed':607,842 'feed-forward':606 'field':399 'fire':114,240 'first':979,1281 'fluid':445 'focus':711 'format':493,631 'forward':608 'frequenc':113,205,241,326,335 'front':758 'function':257,474,1052 'gaba':48,351 'gaba-a':350 'gamma':13,43,118,193,204,263,295,325,332,422,427,615,633,708,910,916,937,1064,1067,1139,1185,1361 'gamma-frequ':324 'gate':83 'general':1110 'generat':41 'generic':740 'global':1029 'grid':882 'grid-cel':881 'gyrus':844 'heterogen':510 'high':112,416,1048 'high-dens':415 'high-frequ':111 'high-resolut':1047 'hippocamp':146,480,626,721,1057 'hippocampus':1190 'human':154,791,941 'hyper':1228 'hyper-synchroni':1227 'hyperexcit':587,1010 'hyperphosphoryl':67 'hypothes':971 'hypothesi':1121,1236,1342 'hypothesis-specif':1120 'hz':909 'identifi':765 'ii':8,39,732,798,851,970,988,1118,1317,1347 'ii-iii':38 'iii':40,1348 'imag':392,1053 'immunohistochem':168 'impact':678 'impair':122,208,614,645 'implic':962 'improv':266,1090,1168 'includ':571 'increas':370,1252 'individu':382,551 'induc':575 'inform':621,1271 'inhibit':1352 'inhibitori':125,1134 'initi':56,1149 'integr':1077,1358 'interneuron':10,33,93,162,225,259,301,375,404,525,600,669,713,1130,1350 'interpret':1123 'intervent':534,1002,1157,1221,1299 'invas':291 'keep':1308 'late':1028 'later':829 'layer':37,731,797,831,987,1117,1346 'lead':100,555 'leav':951 'level':446,696 'light':453 'limit':517 'link':689,826,1143,1326 'local':72 'long':567 'long-term':566 'loop':3,276,306,1156,1298 'loss':655,879 'low':356 'low-dos':355 'maintain':1359 'make':848 'map':984 'marker':1184 'market':1216,1232 'match':1265 'materi':1339 'maxim':398 'maximum':239 'may':516,527 'measur':476 'mechan':23,504,681,1119 'mechanist':688,710 'medial':827 'mediat':97 'memori':140,210,338,492,630,644,890 'mice':190 'microgli':922 'minim':407 'misloc':172 'mnemon':1078 'model':152,271,384,870,926,1292 'modern':772 'modul':348 'molecular':22,458,691 'monitor':314,469 'mood':1108 'mous':151,869 'mri':388,475 'mutat':156 'narrow':1161 'navig':138,489,641 'near':1273 'near-term':1272 'need':1136 'negat':1199 'network':134,302,526,611,684,886,1006 'neural':942 'neurodegener':594 'neurofibrillari':767 'neurofila':452 'neuromodul':899 'neuron':470,654,800,834,878 'neuropatholog':744,811 'non':290,1205 'non-ec':1204 'non-invas':289 'noninvas':936 'nonspecif':1014 'occur':651 'off-target':408 'onset':808 'open':955 'optim':394 'optogenet':248,913 'organ':666 'oscil':44,264,319,423,634,685 'oscillatori':564,1302 'output':833 'p':1041 'p-tau217':1040 'p301s':188 'partial':261 'particular':581 'parvalbumin':9,27 'parvalbumin-posit':26 'patch':219 'patch-clamp':218 'path':840,1076,1174,1246,1374 'patholog':466,513,591,603,676,692,872,1171,1303,1327 'patient':462,515,583 'perfor':837,1373 'perform':211,268 'perisomat':42,124,1351 'pharmacolog':341 'phase':198,340,429,1151 'phase-amplitud':197,428 'phosphoryl':448 'physiolog':1181,1318 'place':751 'plausibl':853 'pmid':812,814,862,896,927,957,959 'point':673,856 'popul':405,805 'posit':28,346 'possibl':573 'potenti':233,507,554 'power':194,424,1068,1212 'precis':46,130,322,535,619,1152 'preclin':148 'price':1250 'primari':438 'process':622 'produc':876 'profil':795 'project':992 'prolong':235 'promis':288 'propag':723 'propos':503,982,1244 'protein':78 'provid':494,686 'pv':29,92,161,224,258,300,374,403,524,599,668,707,712,1129,1166,1180,1219,1349 'pv-center':1218 'pvalb':1343 'quantifi':421 'question':956 'rather':857,1025,1113 'rational':25,1126 'readout':1020,1239 'real':311 'real-tim':310 'reason':1248 'recent':790 'receptor':353 'record':181,419 'reduc':105,192,238,617 'region':435,561,658,771,1208 'relat':500 'releas':49 'relev':496 'remain':256,543 'remap':1082 'reminisc':892 'report':796 'repres':286,670 'requir':1035,1175 'rescu':249,1024 'residu':299 'resolut':1049 'resolv':1179 'respons':372,443 'restor':12,262,294 'result':121,1088 'reveal':170 'review':818 'rhythm':616 'rhythmogenesi':14,119,296,709,714,1362 'risk':1012,1230 'safeti':569,1238 'scaffold':77 'scidex':964 'score':965 'second':999 'seed':775,778,1195,1368 'seek':1159 'segment':57 'seizur':579,1011,1225 'select':158,253,596,803 'sensit':1074 'sensori':915 'separ':977,1079 'serv':456 'sever':522 'sham':1334 'sham-control':1333 'share':725 'shift':1004 'short':947 'short-term':946 'show':191,777,934 'signal':1102 'singl':216,747 'single-cel':215,746 'sleep':1107 'slice':184 'sodium':84,106,358 'spatial':137,209,488,536,640,889,1081 'speci':450 'specif':1116,1122,1260 'spike':32,1148 'spread':549,788 'stage':764,1046,1264,1278 'state':923,1007 'stellat':132 'stimul':280,327,377,532,557,917,938,1202,1336 'stimulation-bas':531 'strategi':273 'stratifi':461 'strength':400 'strong':1031 'stronger':737 'structur':387,1050,1183 'studi':169,221,912,933 'subcellular':71 'subfield':1058 'suffici':874 'suppli':1131 'support':906,1032,1084 'suppress':1364 'synaps':53 'synchron':577 'synchroni':1172,1229 'synergist':362 'system':307,695 'systems-level':694 'tac':4,281,368,542 'target':5,282,379,410,537,983,1285 'task':484,903 'task-bas':483 'tau':17,68,96,155,175,189,227,449,465,512,602,675,722,774,868,871,1038,1142,1194,1322,1367 'tau-link':1141 'tau-medi':95 'tau-seed':773,1193,1366 'tau217':1042 'technic':544 'tempor':129 'temporoammon':839 'tensor':391 'term':568,948,1274 'test':1294 'therapeut':272,365,519 'therefor':1034 'theta':202,318,331,426,1063 'theta-gamma':330,425,1062 'third':1017 'three':976 'time':47,312,323,473,1135,1167 'tissu':784 'togeth':1268 'toler':949 'transcrani':277 'transentorhin':752 'transentorhinal/entorhinal':783 'transgen':150,228 'treatment':344,442 'tune':884 'type':246,794,990,1178,1259 'under':585,682 'underli':136 'unless':1237 'unrespons':529 'upstream':854 'use':381,1198 'util':309 'valid':1173,1245 'variabl':553 'vgsc':86,102 'via':60 'vivo':1289 'voltag':82 'voltage-g':81 'vulner':159,597,733,804,996 'weak':1083 'weaken':1340 'whether':980,1000,1018 'widespread':653,786 'wild':245 'wild-typ':244 'window':520,1163 'without':1008,1095,1169 'work':776 'would':308,1033,1085,1201,1337","before":"'5xfad':186 'aberr':576 'accumul':176 'across':514 'action':232,506 'activ':254,580,729 'ad':21 'adjac':559 'advanc':378 'afterhyperpolar':236 'ai':18,58,90,665,716 'alloster':347 'alter':196 'altern':278 'alzheim':64,648,699 'amplifi':363 'amplitud':199,234,430 'amyloid':590 'anatom':552 'anchor':80 'anim':229 'ankyr':74,98,171,663,714 'ankyring-depend':662,713 'approach':292,380 'assay':214 'assess':486 'associ':588 'axon':55 'base':385,463,485,533 'basket':51 'behavior':213 'biomark':412,440,459 'block':16 'brain':383,560 'burden':467 'burst':728 'capac':115 'cell':52,62,133,179,217 'cellular':680 'cerebrospin':444 'chain':454 'challeng':508,545 'chandeli':61 'channel':85,359 'characterist':646 'circuit':147,627 'clamp':220 'clinic':495 'close':2,275,305 'closed-loop':1,274,304 'cluster':87 'co':343 'co-treat':342 'cognit':267,683 'coher':436 'coincid':173 'compar':242 'compromis':109 'concern':570 'confirm':222 'connect':481,592 'contact':59 'contribut':636 'control':126,247 'converg':672 'correl':206 'cortex':36,166,285,540,704 'cortic':586 'could':361,393,455 'coupl':200,336,431 'creat':604 'critic':76,628 'cross':334,434 'cross-frequ':333 'cross-region':433 'current':107,279,395,548 'cycl':609 'damag':471,523 'decreas':231 'deficit':635 'deliv':321 'deliveri':396 'demonstr':157,251 'densiti':108,417 'depend':664,715 'desynchron':724 'detect':316 'differ':563 'diffus':390 'direct':499,677 'diseas':66,650,701 'dispers':103 'displac':99 'disrupt':19,69,127,660 'dose':357 'due':546 'dynam':565 'dysfunct':612,697 'earli':639 'ec':7 'ec-ii':6 'eeg':313,418 'effect':366,411 'electrophysiolog':180,439 'encod':141,339 'endogen':317 'endpoint':414,497 'enhanc':329,360 'entorhin':35,145,165,183,284,402,479,539,625,703 'entorhinal-hippocamp':144,478,624 'entrain':298 'episod':491,643 'essenti':116 'evid':149 'exhibit':230 'experi':250 'express':153 'fast':31,719 'fast-spik':30 'feed':607 'feed-forward':606 'field':399 'fire':114,240 'fluid':445 'format':493,631 'forward':608 'frequenc':113,205,241,326,335 'function':257,474 'gaba':48,351 'gaba-a':350 'gamma':13,43,118,193,204,263,295,325,332,422,427,615,633,720 'gamma-frequ':324 'gate':83 'generat':41 'heterogen':510 'high':112,416 'high-dens':415 'high-frequ':111 'hippocamp':146,480,626 'human':154 'hyperexcit':587 'hyperphosphoryl':67 'ii':8,39,706 'ii-iii':38 'iii':40,707 'imag':392 'immunohistochem':168 'impact':678 'impair':122,208,614,645 'improv':266 'includ':571 'increas':370 'individu':382,551 'induc':575 'inform':621 'inhibit':711 'inhibitori':125 'initi':56 'integr':717 'interneuron':10,33,93,162,225,259,301,375,404,525,600,669,709 'intervent':534 'invas':291 'layer':37,705 'lead':100,555 'level':446,696 'light':453 'limit':517 'link':689 'local':72 'long':567 'long-term':566 'loop':3,276,306 'loss':655 'low':356 'low-dos':355 'maintain':718 'maxim':398 'maximum':239 'may':516,527 'measur':476 'mechan':23,504,681 'mechanist':688 'mediat':97 'memori':140,210,338,492,630,644 'mice':190 'minim':407 'misloc':172 'model':152,271,384 'modul':348 'molecular':22,458,691 'monitor':314,469 'mous':151 'mri':388,475 'mutat':156 'navig':138,489,641 'network':134,302,526,611,684 'neurodegener':594 'neurofila':452 'neuron':470,654 'non':290 'non-invas':289 'occur':651 'off-target':408 'optim':394 'optogenet':248 'organ':666 'oscil':44,264,319,423,634,685 'oscillatori':564 'p301s':188 'partial':261 'particular':581 'parvalbumin':9,27 'parvalbumin-posit':26 'patch':219 'patch-clamp':218 'path':733 'patholog':466,513,591,603,676,692 'patient':462,515,583 'perfor':732 'perform':211,268 'perisomat':42,124,710 'pharmacolog':341 'phase':198,340,429 'phase-amplitud':197,428 'phosphoryl':448 'point':673 'popul':405 'posit':28,346 'possibl':573 'potenti':233,507,554 'power':194,424 'precis':46,130,322,535,619 'preclin':148 'primari':438 'process':622 'prolong':235 'promis':288 'propos':503 'protein':78 'provid':494,686 'pv':29,92,161,224,258,300,374,403,524,599,668,708 'pvalb':702 'quantifi':421 'rational':25 'real':311 'real-tim':310 'receptor':353 'record':181,419 'reduc':105,192,238,617 'region':435,561,658 'relat':500 'releas':49 'relev':496 'remain':256,543 'repres':286,670 'rescu':249 'residu':299 'respons':372,443 'restor':12,262,294 'result':121 'reveal':170 'rhythm':616 'rhythmogenesi':14,119,296,721 'safeti':569 'scaffold':77 'seed':727 'segment':57 'seizur':579 'select':158,253,596 'serv':456 'sever':522 'show':191 'singl':216 'single-cel':215 'slice':184 'sodium':84,106,358 'spatial':137,209,488,536,640 'speci':450 'spike':32 'spread':549 'stellat':132 'stimul':280,327,377,532,557 'stimulation-bas':531 'strategi':273 'stratifi':461 'strength':400 'structur':387 'studi':169,221 'subcellular':71 'suppress':723 'synaps':53 'synchron':577 'synergist':362 'system':307,695 'systems-level':694 'tac':4,281,368,542 'target':5,282,379,410,537 'task':484 'task-bas':483 'tau':17,68,96,155,175,189,227,449,465,512,602,675,726 'tau-medi':95 'tau-seed':725 'technic':544 'tempor':129 'tensor':391 'term':568 'therapeut':272,365,519 'theta':202,318,331,426 'theta-gamma':330,425 'time':47,312,323,473 'transcrani':277 'transgen':150,228 'treatment':344,442 'type':246 'under':585,682 'underli':136 'unrespons':529 'use':381 'util':309 'variabl':553 'vgsc':86,102 'via':60 'voltag':82 'voltage-g':81 'vulner':159,597 'widespread':653 'wild':245 'wild-typ':244 'window':520 'would':308"},"change_reason":"enrich EC-II vulnerability hypotheses with evidence addenda","created_at":"2026-04-21T02:54:50.595930+00:00"},{"id":4983,"actor_id":null,"entity_type":"hypothesis","entity_id":"h-var-4eca108177","action":"update","diff_json":{"after":"55f94fda6391d29c066a78e105a8489878d1f1e1209402f3aa9df5f9a1dfdc59","before":"ef6259148f85dfa5388f905ab90b6e5ebd8f008638693c694f4e668411a0b0ee"},"change_reason":"enrich EC-II vulnerability hypotheses with evidence addenda","created_at":"2026-04-21T02:54:50.595930+00:00"},{"id":4984,"actor_id":null,"entity_type":"hypothesis","entity_id":"h-var-4eca108177","action":"update","diff_json":{"after":"## Molecular Mechanism and Rationale\n\nParvalbumin-positive (PV+) fast-spiking interneurons in entorhinal cortex layers II-III generate perisomatic gamma oscillations through precisely timed GABA release at basket cell synapses and axon initial segment (AIS) contacts via chandelier cells. In Alzheimer's disease, hyperphosphorylated tau disrupts the subcellular localization of AnkyrinG, a critical scaffolding protein that anchors voltage-gated sodium channel (VGSC) clusters at the AIS of PV interneurons. This tau-mediated AnkyrinG displacement leads to VGSC dispersal and reduced sodium current density, compromising the high-frequency firing capacity essential for gamma rhythmogenesis. The resulting impairment in perisomatic inhibitory control disrupts the temporal precision of stellate cell networks that underlie spatial navigation and memory encoding in the entorhinal-hippocampal circuit.\n\n## Preclinical Evidence\n\nTransgenic mouse models expressing human tau mutations demonstrate selective vulnerability of PV+ interneurons in the entorhinal cortex, with immunohistochemical studies revealing AnkyrinG mislocalization coincident with tau accumulation in these cells. Electrophysiological recordings from entorhinal slices of 5xFAD and P301S tau mice show reduced gamma power and altered phase-amplitude coupling between theta and gamma frequencies, correlating with impaired spatial memory performance in behavioral assays. Single-cell patch-clamp studies confirm that PV interneurons in tau transgenic animals exhibit decreased action potential amplitude, prolonged afterhyperpolarization, and reduced maximum firing frequencies compared to wild-type controls. Optogenetic rescue experiments demonstrate that selective activation of remaining functional PV interneurons can partially restore gamma oscillations and improve cognitive performance in these models.\n\n## Therapeutic Strategy\n\nClosed-loop transcranial alternating current stimulation (tACS) targeting the entorhinal cortex represents a promising non-invasive approach to restore gamma rhythmogenesis by entraining residual PV interneuron networks. The closed-loop system would utilize real-time EEG monitoring to detect endogenous theta oscillations and deliver precisely timed gamma-frequency stimulation to enhance theta-gamma cross-frequency coupling during memory encoding phases. Pharmacological co-treatment with positive allosteric modulators of GABA-A receptors or low-dose sodium channel enhancers could synergistically amplify the therapeutic effects of tACS by increasing the responsiveness of PV interneurons to stimulation. Advanced targeting approaches using individualized brain modeling based on structural MRI and diffusion tensor imaging could optimize current delivery to maximize field strength in entorhinal PV interneuron populations while minimizing off-target effects.\n\n## Biomarkers and Endpoints\n\nHigh-density EEG recordings can quantify gamma oscillation power, theta-gamma phase-amplitude coupling, and cross-regional coherence as primary electrophysiological biomarkers of treatment response. Cerebrospinal fluid levels of phosphorylated tau species and neurofilament light chain could serve as molecular biomarkers to stratify patients based on tau pathology burden and monitor neuronal damage over time. Functional MRI measures of entorhinal-hippocampal connectivity and task-based assessments of spatial navigation and episodic memory formation provide clinically relevant endpoints that directly relate to the proposed mechanism of action.\n\n## Potential Challenges\n\nThe heterogeneity of tau pathology across patients may limit the therapeutic window, as severely damaged PV interneuron networks may be unresponsive to stimulation-based interventions. Precise spatial targeting of entorhinal cortex with tACS remains technically challenging due to current spread and individual anatomical variability, potentially leading to stimulation of adjacent brain regions with different oscillatory dynamics. Long-term safety concerns include the possibility of inducing aberrant synchronization or seizure activity, particularly in patients with underlying cortical hyperexcitability associated with amyloid pathology.\n\n## Connection to Neurodegeneration\n\nThe selective vulnerability of PV interneurons to tau pathology creates a feed-forward cycle of network dysfunction, as impaired gamma rhythms reduce the precision of information processing in entorhinal-hippocampal circuits critical for memory formation. This gamma oscillation deficit contributes to the early spatial navigation and episodic memory impairments characteristic of Alzheimer's disease, occurring before widespread neuronal loss in these regions. The disruption of AnkyrinG-dependent AIS organization in PV interneurons represents a convergence point where tau pathology directly impacts the cellular mechanisms underlying cognitive network oscillations, providing a mechanistic link between molecular pathology and systems-level dysfunction in Alzheimer's disease.\n\n## Evidence enrichment addendum: ecii-pv-gamma-rhythmogenesis\n\n        ### Mechanistic focus\n        PV interneuron rhythmogenesis, AIS disruption, and EC-to-hippocampal tau propagation.\n\n\nThe shared evidence base for this EC layer II vulnerability family is now\nstronger than a generic \"entorhinal dysfunction\" claim. Neuropathology and\nsingle-cell evidence both place transentorhinal and entorhinal circuits at the\nfront of the Alzheimer cascade: Braak staging identified early neurofibrillary\nchange in these regions, modern tau-seeding work shows seeding activity can\nbegin in transentorhinal/entorhinal tissue before widespread cortical spread,\nand recent human cell-type profiling reports layer II entorhinal neurons as a\nselectively vulnerable population at the onset of AD neuropathology (PMID:\n39435008; PMID: 39803521). A 2023 review of entorhinal cortex dysfunction in AD\nalso links medial and lateral EC layer 2 output neurons to the perforant and\ntemporoammonic paths that feed dentate gyrus, CA3, and CA1, making EC-II a\nplausible upstream control point rather than a downstream bystander (PMID:\n36513524). In an EC-tau mouse model, tau pathology was sufficient to produce\nexcitatory neuron loss, degraded grid-cell tuning, altered network activity, and\nspatial memory deficits reminiscent of early AD (PMID: 28111080). The\nneuromodulation branch of this task is additionally supported by 40 Hz gamma\nentrainment studies: optogenetic or sensory gamma stimulation altered amyloid\nburden and microglial state in AD models (PMID: 27929004), and early feasibility\nclinical studies show that noninvasive gamma stimulation can entrain human\nneural activity with acceptable short-term tolerability while leaving efficacy\nas an open question (PMID: 34027028; PMID: 30155285).\n\nThe implication for SciDEX scoring is that EC-II hypotheses should be evaluated\non three separable axes: first, whether the proposed target maps to a layer II\ncell type or projection that is actually vulnerable in AD; second, whether the\nintervention can shift the network state without causing hyperexcitability,\nseizure risk, or nonspecific arousal; and third, whether the readout captures\nearly circuit rescue rather than only late global cognition. Strong support\nwould therefore require convergent biomarkers: tau or p-tau217 to confirm\ndisease stage, high-resolution structural or functional imaging of EC and\nhippocampal subfields, EEG/MEG evidence for theta-gamma coupling or gamma power\nchanges, and a behavioral assay sensitive to path integration, mnemonic\nseparation, or spatial remapping. Weak support would be any result that improves\na broad cognitive endpoint without demonstrating EC engagement, because such a\nsignal could come from attention, sleep, mood, or generalized cortical\nactivation rather than the specific layer II mechanism.\n\n\n        ### Hypothesis-specific interpretation\n        The added rationale is that PV interneurons supply the fast inhibitory timing needed for coherent gamma, while tau-linked AIS disruption can degrade spike initiation and phase precision. A closed-loop intervention should seek a narrow entrainment window in which PV timing improves without driving pathological synchrony.\n\n        ### Validation path\n        Require cell-type-resolved PV physiology, AIS structural markers, gamma coherence between EC and hippocampus, and a tau-seeding endpoint. A useful negative control would stimulate a non-EC cortical region with the same power envelope.\n\n        ### Counterevidence and market caveats\n        PV-centered interventions are exposed to seizure and hyper-synchrony risk. The market should discount the hypothesis unless safety readouts are built into the proposed validation path. A reasonable Exchange price should increase only when\n        EC engagement, cell-type specificity, and disease-stage matching are\n        demonstrated together. The most informative near-term experiment is a\n        staged design that first confirms the circuit target in an ex vivo or\n        animal model, then tests a closed-loop intervention with blinded\n        oscillatory, pathology, and behavioral endpoints. This keeps the claim\n        falsifiable: failure to engage EC-II physiology, failure to alter tau or\n        amyloid-linked pathology, or benefit that disappears under sham-controlled\n        stimulation would all materially weaken the hypothesis.\n","before":"## Molecular Mechanism and Rationale\n\nParvalbumin-positive (PV+) fast-spiking interneurons in entorhinal cortex layers II-III generate perisomatic gamma oscillations through precisely timed GABA release at basket cell synapses and axon initial segment (AIS) contacts via chandelier cells. In Alzheimer's disease, hyperphosphorylated tau disrupts the subcellular localization of AnkyrinG, a critical scaffolding protein that anchors voltage-gated sodium channel (VGSC) clusters at the AIS of PV interneurons. This tau-mediated AnkyrinG displacement leads to VGSC dispersal and reduced sodium current density, compromising the high-frequency firing capacity essential for gamma rhythmogenesis. The resulting impairment in perisomatic inhibitory control disrupts the temporal precision of stellate cell networks that underlie spatial navigation and memory encoding in the entorhinal-hippocampal circuit.\n\n## Preclinical Evidence\n\nTransgenic mouse models expressing human tau mutations demonstrate selective vulnerability of PV+ interneurons in the entorhinal cortex, with immunohistochemical studies revealing AnkyrinG mislocalization coincident with tau accumulation in these cells. Electrophysiological recordings from entorhinal slices of 5xFAD and P301S tau mice show reduced gamma power and altered phase-amplitude coupling between theta and gamma frequencies, correlating with impaired spatial memory performance in behavioral assays. Single-cell patch-clamp studies confirm that PV interneurons in tau transgenic animals exhibit decreased action potential amplitude, prolonged afterhyperpolarization, and reduced maximum firing frequencies compared to wild-type controls. Optogenetic rescue experiments demonstrate that selective activation of remaining functional PV interneurons can partially restore gamma oscillations and improve cognitive performance in these models.\n\n## Therapeutic Strategy\n\nClosed-loop transcranial alternating current stimulation (tACS) targeting the entorhinal cortex represents a promising non-invasive approach to restore gamma rhythmogenesis by entraining residual PV interneuron networks. The closed-loop system would utilize real-time EEG monitoring to detect endogenous theta oscillations and deliver precisely timed gamma-frequency stimulation to enhance theta-gamma cross-frequency coupling during memory encoding phases. Pharmacological co-treatment with positive allosteric modulators of GABA-A receptors or low-dose sodium channel enhancers could synergistically amplify the therapeutic effects of tACS by increasing the responsiveness of PV interneurons to stimulation. Advanced targeting approaches using individualized brain modeling based on structural MRI and diffusion tensor imaging could optimize current delivery to maximize field strength in entorhinal PV interneuron populations while minimizing off-target effects.\n\n## Biomarkers and Endpoints\n\nHigh-density EEG recordings can quantify gamma oscillation power, theta-gamma phase-amplitude coupling, and cross-regional coherence as primary electrophysiological biomarkers of treatment response. Cerebrospinal fluid levels of phosphorylated tau species and neurofilament light chain could serve as molecular biomarkers to stratify patients based on tau pathology burden and monitor neuronal damage over time. Functional MRI measures of entorhinal-hippocampal connectivity and task-based assessments of spatial navigation and episodic memory formation provide clinically relevant endpoints that directly relate to the proposed mechanism of action.\n\n## Potential Challenges\n\nThe heterogeneity of tau pathology across patients may limit the therapeutic window, as severely damaged PV interneuron networks may be unresponsive to stimulation-based interventions. Precise spatial targeting of entorhinal cortex with tACS remains technically challenging due to current spread and individual anatomical variability, potentially leading to stimulation of adjacent brain regions with different oscillatory dynamics. Long-term safety concerns include the possibility of inducing aberrant synchronization or seizure activity, particularly in patients with underlying cortical hyperexcitability associated with amyloid pathology.\n\n## Connection to Neurodegeneration\n\nThe selective vulnerability of PV interneurons to tau pathology creates a feed-forward cycle of network dysfunction, as impaired gamma rhythms reduce the precision of information processing in entorhinal-hippocampal circuits critical for memory formation. This gamma oscillation deficit contributes to the early spatial navigation and episodic memory impairments characteristic of Alzheimer's disease, occurring before widespread neuronal loss in these regions. The disruption of AnkyrinG-dependent AIS organization in PV interneurons represents a convergence point where tau pathology directly impacts the cellular mechanisms underlying cognitive network oscillations, providing a mechanistic link between molecular pathology and systems-level dysfunction in Alzheimer's disease."},"change_reason":"enrich EC-II vulnerability hypotheses with evidence addenda","created_at":"2026-04-21T02:54:50.595930+00:00"},{"id":4985,"actor_id":null,"entity_type":"hypothesis","entity_id":"h-var-4eca108177","action":"update","diff_json":{"after":0.78,"before":1.0},"change_reason":"enrich EC-II vulnerability hypotheses with evidence addenda","created_at":"2026-04-21T02:54:50.595930+00:00"}]}